Dme Capital Management, LP Gain Therapeutics, Inc. Call Options Transaction History
Dme Capital Management, LP
- $2.4 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GANX
# of Institutions
23Shares Held
2.39MCall Options Held
10KPut Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.01 Million0.1% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$575,4980.01% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$467,7910.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA145KShares$249,7730.0% of portfolio
-
Telemetry Investments, L.L.C. New York, NY123KShares$211,5600.61% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $20.4M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...